Anzeige
Mehr »
Login
Sonntag, 29.12.2024 Börsentäglich über 12.000 News von 681 internationalen Medien
Wie Trumps Aussagen die Krypto-Landschaft verändern könnten: Beobachten Sie diese Aktie jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
1.086 Leser
Artikel bewerten:
(2)

Barnsley Hospital and Sky Medical Technology Win Prestigious 2020 Bionow Award

Finanznachrichten News

Obstetrics blood clot prevention study recognised as Healthcare Project of the Year

HIGH WYCOMBE, England, Feb. 11, 2021 /PRNewswire/ -- A partnership between Barnsley Hospital NHS Foundation Trust and Sky Medical Technology (Sky), a UK industry-leading medical devices company, has been recognised at the February 2021 Bionow Awards ceremony, for its use of the innovative geko device in preventing blood clots in high-risk pregnant patients.

The award category, Healthcare Project of the Year, celebrates collaboration. Barnsley Hospital NHS Foundation Trust worked in partnership with Sky to carry out a pilot observational study to determine whether Sky's innovative neuromuscular electrostimulation device, the geko, was suitable for blood clot prevention in high-risk pregnant patients where the current standard of care is not suitable.

The current standard of care recommends anticoagulants or mechanical compression which cannot be used by some pregnant patients for a variety of reasons, including severe pre-eclampsia, where patients might need urgent delivery, or post-partum haemorrhage. Two percent of the overall patient population cannot be treated with this current standard of care.

As such, the Barnsley Hospital Maternity Unit worked with Sky to create a study focused on 90 patients who were contraindicated to the current standard of care. All 90 were prescribed the geko, a small watch-sized device that sticks to the leg and increases blood flow, via painless electrical pulses, at some stage during labour - more than half were prescribed geko as the only method of blood clot prevention.

Following the study Barnsley Hospital became the first maternity unit in the UK to adopt the innovative geko device, and two other hospitals have since followed.

Dr Mona Fawzy, Consultant in Obstetrics & Gynaecology, Labour Ward Lead and Deputy Obstetric Lead at Barnsley Hospital, said: "We are delighted to have won. Recognising the need to provide prophylaxis to at risk patients, we embraced the opportunity to examine the role of the geko device in the obstetrics population. Our findings show the geko device is safe and well-tolerated and can be used to protect patients until it is safe to prescribe blood thinning drugs. We are pleased to be the first NHS maternity unit able to provide a blood clot prevention strategy for all high-risk patients in our care."

James Fry, Partner and Head of the life sciences practice for Mills & Reeve, sponsor of the award said: "The work undertaken by Sky Medical Technology in collaboration with Barnsley Hospital NHS Foundation Trust showcases yet another stand-out year of achievement for life sciences in the North, where a strong spirit of partnership between industry and the NHS has led to the development of an important new therapy for obstetrics blood clot prevention. We are honoured to sponsor Bionow's Healthcare Project of the Year Award. The companies shortlisted made it a strong category this year but this collaboration has resulted in exceptional read out data and a product that is clearly meeting an unmet clinical need, in a real area of need".

Bernard Ross, CEO of Sky Medical Technology, comments: "I would like to thank Bionow and Mills & Reeve. We are extremely proud to again win in the category: Healthcare Project of the Year. It celebrates the very high priority we place on partnering with our NHS colleagues who, on top of their full-time jobs, and in a challenging environment, are willing to give-up additional time in pursuit of innovation for better patient outcomes."

"Deep Vein Thrombosis is the highest cause of maternal death in the developed world - and I applaud Dr Fawzy and her clinical team at the Barnsley Hospital NHS Foundation Trust, for leading in the field in embracing a new treatment that ensures all at-risk patients, during pregnancy, can have a safe method of blood clot prevention. It is to them this award goes, for their vision and hard work and I thank them."

About the geko device

NICE guidance (MTG19) recommends use of the geko device for VTE prophylaxis in all hospital patients where standard prophylaxis treatments are impractical or contraindicated. The geko is a neuromuscular electrostimulation device which prevents blood stasis in the deep veins of the calf by activation of foot and calf muscle pumps via stimulation of the common peroneal nerve. Weighing just 10g, silent in operation and with no wires or leads, the battery powered geko is a daily disposable device that is self-adhesive and comfortable to wear. www.gekodevices.com

About Barnsley Hospital NHS Foundation Trust

Barnsley is a 350+ bed hospital serving a population of over a quarter of a million people in the Barnsley area, providing a full range of district hospital services to the local community and surrounding area. These include: emergency department services, outpatient clinics, inpatient services and maternity care, where each year approximately 2,800 babies are born.

Barnsley Hospital champions its clinicians to embrace innovation and partner with industry to pioneer new models of care, so that its patients can be amongst the first to benefit from hugely exciting medical advances. https://www.barnsleyhospital.nhs.uk/

About Sky Medical Technology Ltd & Firstkind and

Sky Medical Technology, the parent of Firstkind Ltd, is a highly innovative UK based medical devices company that has developed a ground-breaking neuromuscular electrostimulation technology platform, OnPulse. The company develops a range of products tailored to the needs of different medical application areas selling both direct and through strategic partnerships or distributors in each major clinical area. Clinical areas of interest include DVT prevention, oedema treatment and prevention and wound healing. The goal in each clinical area is to improve clinical outcomes and patient care whilst saving health system resources. www.gekodevices.com

www.skymedtech.com

Video - https://mma.prnewswire.com/media/1436626/Sky_Medical_Technology.mp4
Photo - https://mma.prnewswire.com/media/1436627/Sky_Medical_Technology_geko_device.jpg
Logo - https://mma.prnewswire.com/media/1340942/Sky_Medical_Logo.jpg
Logo - https://mma.prnewswire.com/media/1436625/Bionow_Award_2020_Logo.jpg

The geko device on the leg (PRNewsfoto/Sky Medical Technology Ltd.)

Sky Medical Technology Logo (PRNewsfoto/Sky Medical Technology Ltd.)

2020 Bionow Award Logo (PRNewsfoto/Sky Medical Technology Ltd.)

© 2021 PR Newswire
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.